降血糖藥物分類：Diabetes M

Antidiabetic Medication: the “Diabetes M” Approach

第二型糖尿病是全身血管異常之疾病，會造成多發性器官併發症，因此耗用大量醫療資源。近年來有關其藥物治療有很大的進展，本文以Diabetes M綜括了對糖尿病之處置及藥物治療，其中D代表糖尿病診斷標準(Diagnosis)、二肽基胜肽酶-4抑制劑(DPP-4 inhibitors)、飲食(Diet)治療，i表示腸泌胰素(incretin) 類似物、胰島素(insulin)，a表示糖苷酶抑制劑(α-glucosidase inhibitors)、糊精類似物(amylin analogues)、另類療法(alternative medicine)，b表示雙胍類(biguanides)、行為改變(behavior modification)、體重控制(body weight control)，e表示評估血管併發症及心理社會狀態(evaluation for microvascular and macrovascular complications and psychosocial condition)，t表示硫氮烷二酮類(thiazolidinediones; TZDs)，e表示運動(exercise)、衛教(education)，s表示磺醯尿素類(sulfonylurea s)，M表示美格替耐(Meglitinides)。Diabetes M提供實用和有系統、完整之處置及藥物治療指示，對醫療人員在糖尿病之用藥或教學研究上可提供相當的助益。

Type 2 diabetes mellitus (DM) is a disorder of whole body vasculopathy and results in multiple organ complications. It also consumes massive health care expenditure. Because of the advances in the treatment of diabetes, we have proposed a comprehensive management plan assembled through a 'Diabetes M' approach: 'D' for diagnosis, DPP-4 inhibitors, and diet control, 'i' for incretin and insulin, 'a' for α-glucosidase inhibitors, amylin analogues, alternative medicine and assessment, 'b' for biguanides, behavior modification, and body weight control, 'e' for evaluation of microvascular and macrovascular complications and psychosocial condition, 't' for thiazolidinediones, 'e' for exercise and education, 's' for sulfonylureas, and 'M' for meglitinides. The 'Diabetes M' approach can provide a practical and comprehensive plan for the use of medication for type 2 diabetes. We anticipate that this approach can serve as a reference for education about and research on DM.